Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 15/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 14/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 14/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966917 | 0.98 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL21881665 | 0.98 | GNAO1 (0.39) | GNAO1GNAI3GNAI1EPHX1CHRM1 | |
| SCHEMBL21880925 | 0.94 | GNAO1 (0.37) | GNAO1GNAI3GNAI1EPHX1CHRM1 | |
| SCHEMBL21880962 | 0.80 | CNR1 (0.31) | — | |
| SCHEMBL21881668 | 0.77 | GNAO1 (0.40) | GNAO1GNAI3GNAI1CHRM1 | |
| SCHEMBL24702211 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL19184806 | 0.74 | — | — | |
| SCHEMBL19225687 | 0.73 | GNAI3 (0.33) | GNAO1GNAI3GNAI1 | |
| SCHEMBL19230311 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL24648654 | 0.71 | GNAI3 (0.32) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | GNAO1 644/4885GNAI3 376/4885GNAI1 307/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | GNAO1 644/4885GNAI3 376/4885GNAI1 307/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | GNAO1 644/4885GNAI3 376/4885GNAI1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.